Brief: Transcode Therapeutics Inc - Plan To Submit IND To FDA In Q1 Of 2024

Transcode Therapeutics

04/01/2024 13:09

Jan 4 (Reuters) - Transcode Therapeutics Inc  RNAZ.O :
    * PLAN TO SUBMIT AN IND TO FDA IN Q1 OF 2024 TO SUPPORT A
PROPOSED
PHASE 1 CLINICAL TRIAL OF TTX-MC138
    * TAKEN DECISIVE ACTIONS TO REDUCE EXPENSES WITHOUT
COMPROMISING
OUR COMMITMENT TO INNOVATION AND PROGRESS
    * REVIEWED OPERATIONS TO IDENTIFY AREAS TO DELAY OR REDUCE
EXPENDITURES INCLUDING REDUCTION IN HEADCOUNT TO 11 AT END OF
2023
    * IMPLEMENTED SIZABLE TEMPORARY SALARY REDUCTIONS FOR SENIOR
MANAGEMENT
    * OUR BOARD OF DIRECTORS HAS PUT A PROPOSAL BEFORE
SHAREHOLDERS
FOR A REVERSE STOCK SPLIT
    * CAPITAL IS NEEDED VERY SOON AS HAVE UNTIL JAN 22, 2024, TO
SHOW
NASDAQ THAT WE ARE ON-TRACK WITH PLAN TO REGAIN COMPLIANCE
    * HAVE SUBMITTED APPLICATIONS FOR NONDILUTIVE GOVERNMENT
FUNDING
AND ARE AWAITING FUNDING DECISIONS
    * PARTNERSHIP DISCUSSIONS WITH PHARMA CO FOR DEVELOPMENT OF
SEVERAL O PRECLINICAL PROGRAMS INCLUDING TTX-MRNA, TTX-CRISPR,
AND TTX-SIRNA

Source text for Eikon:  ID:nGNX93gJJH 
Further company coverage:  RNAZ.O 

 ((Reuters.Briefs@thomsonreuters.com;))